Who is sponsoring NCT05172466?

NCT05172466 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT05172466?

Interventions in NCT05172466: BeCare application.

What condition does NCT05172466 study?

NCT05172466 studies Relapsing-remitting Multiple Sclerosis (RRMS).

Is NCT05172466 still recruiting?

NCT05172466 is currently withdrawn. Last updated 25 November 2022.

Last reviewed 2022-11-25 · How we verify

NCT05172466

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Withdrawn NA Last updated 25 November 2022

What this trial tests

NA trial testing BeCare application in Relapsing-remitting Multiple Sclerosis (RRMS). Withdrawn.

Timeline

31 October 2022

Primary endpoint
11 November 2022

11 November 2022

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Start date	31 October 2022
Primary completion	11 November 2022
Estimated completion	11 November 2022
Sites	1 location across United States

Drugs / interventions tested

BeCare application

Conditions studied

Relapsing-remitting Multiple Sclerosis (RRMS) — all drugs for Relapsing-remitting Multiple Sclerosis (RRMS) →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 18 to 60, any sex, with Relapsing-remitting Multiple Sclerosis (RRMS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this proposal is to use the BeCare App to (1) determine changes in "Feel Good Effect", or "Restoring Physiologic Homeostasis(RPH)"for individuals with relapsing-remitting MS (RRMS) before and after starting Natalizumab therapy and (2) Compare BeCare-derived with clinically-derived performance metrics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Relapsing-remitting Multiple Sclerosis (RRMS)

Currently open trials in the same condition.

NCT06700343 — Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) · Phase 3 · recruiting
NCT05811416 — A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participant · active not recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05172466 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 25 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing